Analyst consensus rating
Prelude Therapeutics Analyst Rating: none
Direct answer
Prelude Therapeutics's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.20.
Forecast evidence checked November 10, 2026.
Get free Prelude Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.76
- Average price target
- $9.20
- High price target
- $12.00
- Low price target
- $6.00
- Low target gap
- +59.6%
- Target upside
- +144.7%
- High target gap
- +219.1%
- Target range width
- 159.6%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- November 10, 2026
- Valid through
- November 17, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Prelude Therapeutics?
Prelude Therapeutics has a verified none consensus. The same dataset has an average price target of $9.20.
How far are Prelude Therapeutics's low and high targets from the recorded price?
The low target implies +59.6%, while the high target implies +219.1%.
How many analysts are included in Prelude Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Prelude Therapeutics's target upside or downside calculated?
The average target of $9.20 is divided by the recorded price of $3.76, then one is subtracted to produce +144.7%. This does not guarantee a future return.
When was Prelude Therapeutics's analyst forecast verified?
The data was verified on 2026-11-10. The dataset is valid through 2026-11-17.